Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.

Myeloid sarcoma (MS) is currently considered equivalent to de novo acute myeloid leukemia (AML); however, the relationship between these entities is poorly understood. This retrospective multi-institutional cohort study compared 43 MS with NPM1 mutation to 106 AML with NPM1 mutation. Compared to AML, MS had more frequent cytogenetic abnormalities including complex karyotype (p =.009 and p =.007, respectively) and was enriched in mutations of genes involved in histone modification, including ASXL1 (p =.007 and p =.008, respectively). AML harbored a higher average number of gene mutations (p =.002) including more frequent PTPN11 mutations (p <.001) and mutations of DNA-methylating genes including DNMT3A and IDH1 (both p <.001). MS had significantly shorter overall survival (OS) than AML (median OS: 44.9 vs. 93.2 months, respectively, p =.037). MS with NPM1 mutation has a unique genetic landscape, and poorer OS, compared to AML with NPM1 mutation. First study comparing genetic profiles of MS and AML with a common disease-defining lesion. NPM1^Mut MS may be genetically distinct from NPM1^Mut AML. NPM1^Mut MS may have inferior overall survival compared to NPM1^Mut AML. [ABSTRACT FROM AUTHOR]